Prof. Dr. med. Silke Gillessen Sommer
Macrocytosis and cobalamin deficiency in patients treated with sunitinib
Gillessen Sommer S, Graf L, Korte W, Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. The New England journal of medicine 2007; 356:2330-1.
31.05.2007Macrocytosis and cobalamin deficiency in patients treated with sunitinib
31.05.2007The New England journal of medicine 2007; 356:2330-1
Gillessen Sommer Silke, Graf Lukas, Korte Wolfgang, Cerny Thomas
Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure
Inauen R, Cathomas R, Boehm T, Pestalozzi B, Gillessen Sommer S, von Moos R. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007; 72:209-10.
01.01.2007Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure
01.01.2007Oncology 2007; 72:209-10
Inauen Roman, Cathomas R, Boehm T, Pestalozzi B C, Gillessen Sommer Silke, von Moos R
Sinnvoll?
Templeton A, Gillessen Sommer S. Sinnvoll?. Schweiz Med Forum 2007; 7:469.
01.01.2007Sinnvoll?
01.01.2007Schweiz Med Forum 2007; 7:469
Templeton Arnoud, Gillessen Sommer Silke
Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis
Rohr L, Klaeser B, Jörger M, Kluckert J, Cerny T, Gillessen Sommer S. Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis. Onkologie 2007:320-323.
01.01.2007Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis
01.01.2007Onkologie 2007:320-323
Rohr L., Klaeser B, Jörger Markus, Kluckert Jörg-Thomas, Cerny Thomas, Gillessen Sommer Silke
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Waeckerle-Men Y, Groettrup M, Ludewig B, Cerny T, Ackermann D, Schmid H, Böhme C, von Moos R, Fopp M, Uetz-von Allmen E, Gillessen Sommer S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer immunology, immunotherapy : CII 2006; 55:1524-33.
01.12.2006Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
01.12.2006Cancer immunology, immunotherapy : CII 2006; 55:1524-33
Waeckerle-Men Ying, Groettrup Marcus, Ludewig Burkhard, Cerny Thomas, Ackermann Daniel, Schmid Hans-Peter, Böhme Christel, von Moos Roger, Fopp Markus, Uetz-von Allmen Edith, Gillessen Sommer Silke
Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma
Schlaeppi M, Korte W, von Moos R, Cerny T, Gillessen Sommer S. Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma. Onkologie 2006; 29:531-3.
01.11.2006Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma
01.11.2006Onkologie 2006; 29:531-3
Schlaeppi Marc, Korte Wolfgang, von Moos Roger, Cerny Thomas, Gillessen Sommer Silke
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
01.04.2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
01.04.2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
[Treatment possibilities for patients with advanced prostate cancer]
Gillessen Sommer S, Strasser F. [Treatment possibilities for patients with advanced prostate cancer]. Therapeutische Umschau. Revue thérapeutique 2006; 63:157-62.
01.02.2006[Treatment possibilities for patients with advanced prostate cancer]
01.02.2006Therapeutische Umschau. Revue thérapeutique 2006; 63:157-62
Gillessen Sommer Silke, Strasser Florian
Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
Waeckerle-Men Y, Allmen E, von Moos R, Classon B, Scandella E, Schmid H, Ludewig B, Groettrup M, Gillessen Sommer S. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. The Prostate 2005; 64:323-31.
01.09.2005Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
01.09.2005The Prostate 2005; 64:323-31
Waeckerle-Men Ying, Allmen Edith Uetz-von, von Moos Roger, Classon Brendan J, Scandella Elke, Schmid Hans-Peter, Ludewig Burkhard, Groettrup Marcus, Gillessen Sommer Silke
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity
Nieuwenhuis E, Blumberg R, Dranoff G, Strominger J, Balk S, Taniguchi M, Exley M, Scheper R, Gillessen Sommer S, Wilson S. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Experimental dermatology 2005; 14:250-8.
01.04.2005CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity
01.04.2005Experimental dermatology 2005; 14:250-8
Nieuwenhuis Edward E S, Blumberg Richard S, Dranoff Glenn, Strominger Jack L, Balk Steven P, Taniguchi Masaru, Exley Mark A, Scheper Rik J, Gillessen Sommer Silke, Wilson S Brian
Von Hippel-Lindau disease--a rare disease important to recognize
Jörger M, Köberle D, Neumann H, Gillessen Sommer S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005; 28:159-63.
01.03.2005Von Hippel-Lindau disease--a rare disease important to recognize
01.03.2005Onkologie 2005; 28:159-63
Jörger Markus, Köberle Dieter, Neumann Hartmut P H, Gillessen Sommer Silke
Hypertriglyceridemia as a possible risk factor for prostate cancer
Wuermli L, Jörger M, Henz S, Schmid H, Riesen W, Thomas G, Krek W, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate cancer and prostatic diseases 2005; 8:316-20.
01.01.2005Hypertriglyceridemia as a possible risk factor for prostate cancer
01.01.2005Prostate cancer and prostatic diseases 2005; 8:316-20
Wuermli L, Jörger Markus, Henz Samuel, Schmid H-P, Riesen W F, Thomas G, Krek W, Cerny Thomas, Gillessen Sommer Silke
Hypertriglyceridemia as a possible risk factor for prostate cancer
Würmli L, Jörger M, Henz S, Schmid H, Riesen W, Thomas G, Krek W, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005; 8:316-320.
01.01.2005Hypertriglyceridemia as a possible risk factor for prostate cancer
01.01.2005Prostate Cancer Prostatic Dis 2005; 8:316-320
Würmli LIneta, Jörger Markus, Henz Samuel, Schmid Hans-Peter, Riesen Walter F, Thomas G, Krek W, Cerny Thomas, Gillessen Sommer Silke
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
Prikler L, Scandella E, Men Y, Engeler D, Diener P, Gillessen Sommer S, Ludewig B, Schmid H. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. Aktuelle Urologie 2004; 35:326-30.
01.08.2004[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
01.08.2004Aktuelle Urologie 2004; 35:326-30
Prikler L, Scandella Elke, Men Y, Engeler Daniel, Diener P-A, Gillessen Sommer Silke, Ludewig Burkhard, Schmid H-P
[Mabthera for treatment of malignant lymphoma]
Cerny T, Hitz F, Gillessen Sommer S. [Mabthera for treatment of malignant lymphoma]. Therapeutische Umschau. Revue thérapeutique 2004; 61:379-83.
01.06.2004[Mabthera for treatment of malignant lymphoma]
01.06.2004Therapeutische Umschau. Revue thérapeutique 2004; 61:379-83
Cerny Thomas, Hitz Felicitas, Gillessen Sommer Silke
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny T, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer S, Dietrich D, Bernhard J, Schmid H. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. British journal of cancer 2004; 90:1312-7.
05.04.2004Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
05.04.2004British journal of cancer 2004; 90:1312-7
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny Thomas, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer Silke, Dietrich D, Bernhard J, Schmid H-P
Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy
Waeckerle-Men Y, Scandella E, Uetz-von Allmen E, Ludewig B, Gillessen Sommer S, Merkle H, Gander B, Groettrup M. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. Journal of immunological methods 2004; 287:109-24.
01.04.2004Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy
01.04.2004Journal of immunological methods 2004; 287:109-24
Waeckerle-Men Ying, Scandella Elke, Uetz-von Allmen Edith, Ludewig Burkhard, Gillessen Sommer Silke, Merkle Hans P, Gander Bruno, Groettrup Marcus
Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer
Jörger M, Warzinek T, Klaeser B, Kluckert J, Schmid H, Gillessen Sommer S. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63:778-80.
01.04.2004Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer
01.04.2004Urology 2004; 63:778-80
Jörger Markus, Warzinek T, Klaeser B, Kluckert J T, Schmid H-P, Gillessen Sommer Silke
Major tumor regression afrer paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer
Jörger M, Warzinek T, Klaeser B, Kluckert J, Schmid H, Gillessen Sommer S. Major tumor regression afrer paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63:778-780.
01.04.2004Major tumor regression afrer paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer
01.04.2004Urology 2004; 63:778-780
Jörger Markus, Warzinek T, Klaeser B, Kluckert Jörg-Thomas, Schmid Hans-Peter, Gillessen Sommer Silke
CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2
Scandella E, Men Y, Legler D, Gillessen Sommer S, Prikler L, Ludewig B, Groettrup M. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2004; 103:1595-601.
01.03.2004CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2
01.03.2004Blood 2004; 103:1595-601
Scandella Elke, Men Ying, Legler Daniel F, Gillessen Sommer Silke, Prikler Ladislav, Ludewig Burkhard, Groettrup Marcus